• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.57% Nasdaq Up2.12%

    Sangamo Biosciences Inc. (SGMO)

    -NasdaqGS
    5.56 Up 0.42(8.17%) Jun 28, 4:00PM EDT
    |After Hours : 5.56 0.00 (0.00%) Jun 28, 4:39PM EDT
    ProfileGet Profile for:
    Sangamo Biosciences Inc.
    501 Canal Boulevard
    Richmond, CA 94804
    United States - Map
    Phone: 510-970-6000
    Fax: 510-236-8951
    Website: http://www.sangamo.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:119

    Business Summary 

    Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome modification and gene regulation. The ZFPs can also be linked to a cleavage domain of a restriction endonuclease to create zinc finger nucleases (ZFNs), proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its lead ZFP Therapeutic candidate include SB-728-T, a ZFN-mediated autologous cell product for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) is in Phase II and Phase I/II clinical trials. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B and MPS I, a lysosomal storage disorder (LSD); and proprietary preclinical programs in hemophilia A, other LSDs. It has collaborative partnerships with Biogen Inc. (Biogen) to research, develop, and commercialize the preclinical ZFP Therapeutic development program in hemoglobinopathies, including sickle cell disease and beta-thalassemia; and with Shire International GmbH to research, develop, and commercialize the preclinical ZFP Therapeutic development program in Huntington’s disease. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sangamo Biosciences Inc.

    Corporate Governance 
    Sangamo Biosciences Inc.’s ISS Governance QuickScore as of Jun 1, 2016 is 3. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Edward O. Lanphier II, 59
    Founder, Chairman and Member of Clinical Review Committee
    1.02M1.19M
    Mr. H. Ward Wolff , 67
    Chief Financial Officer and Exec. VP
    556.00K799.00K
    Dr. Dale G. Ando M.D., 62
    Chief Medical Officer and VP of Therapeutic Devel.
    585.00K888.00K
    Dr. Geoffrey M. Nichol M.D., M.B., Ch.B., M.B.A., 61
    Exec. VP of R&D
    649.00K0.00
    Dr. Alexander Macrae M.B., Ch.B, Ph.D., MRCP,
    Chief Exec. Officer, Pres and Director
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders